Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
M Hasib Sidiqi(Curtin University), Morie A. Gertz(Medical University of South Carolina), Francis K. Buadi, Mohammed A. Aljama(Juravinski Cancer Centre), Nelson Leung(WinnMed), Irbaz Bin Riaz(Mayo Clinic), Shaji Kumar(Mayo Clinic), Prashant Kapoor, Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Angela Dispenzieri(Mayo Clinic), William J. Hogan(Mayo Clinic), David Dingli
Cited by 20
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k